Test Price
2,800 AED✅ Home Collection Available
TAT Gene Tyrosinemia Type 2 (NGS) Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
This advanced NGS-based genetic test analyses the entire coding region of the TAT gene to identify pathogenic variants responsible for Tyrosinemia Type 2, a rare autosomal recessive metabolic disorder that if untreated can lead to corneal opacities, painful palmoplantar hyperkeratosis, and neurological involvement. The test delivers precise molecular confirmation with full clinical interpretation support.
- Accuracy Guarantee: ≥99.9% Diagnostic Sensitivity – ISO 9001:2015 accredited laboratory processing with complete gene sequencing via NGS.
- Premium Logistics: Paid Hospital-Grade Home Collection through ISO-Certified Cold-Chain VIP Mobile Phlebotomy, available 8 AM–11 PM daily.
- Clinical Guidance: Complimentary telephonic post-test clinical interpretation with a DHA-licensed Consultant Medical Genetics specialist.
- Insurance: Direct billing verification via WhatsApp +971 54 548 8731 – pre-approval before sample collection.
Test Overview & Methodology
This NGS-based genetic test analyses the entire coding region of the TAT gene to identify pathogenic variants responsible for Tyrosinemia Type 2. Next Generation Sequencing (NGS) provides comprehensive coverage of coding exons and flanking intronic regions, enabling detection of known pathogenic variants as well as novel mutations that targeted panels may miss. The assay is designed to confirm or exclude a molecular diagnosis of tyrosinemia type 2 in symptomatic individuals, carriers, and at-risk family members.
| Feature | Our Test – TAT Gene NGS | Closest Alternative |
|---|---|---|
| Method | NGS – full gene sequencing (coding exons ± flanking intronic regions) | Targeted mutation panel (limited variants) |
| Diagnostic Yield | >99.9% for known pathogenic variants; novel variant detection possible | ~85–90% (common mutations only) |
| Turnaround Time | 3 – 4 Weeks | 4 – 6 Weeks |
| Regulatory Compliance | ISO 9001:2015 + UAE DHA/MOHAP guidelines + UAE PDPL | Variable |
Physician Insight & Safety Protocols
“As a Consultant Medical Genetics specialist, I understand the anxiety that accompanies genetic testing for inherited metabolic conditions. This analysis provides vital molecular confirmation, but results must be interpreted in the context of your full clinical history, biochemical profile, and family pedigree. A positive variant does not guarantee symptom onset, and a negative result does not entirely exclude all possible genetic causes for your condition. Always discuss results with your managing physician before making any treatment changes.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403
Important Medication Notice
Do not discontinue any prescribed medication, dietary therapy, or tyrosine-restricted diet without consulting your managing physician. This genetic test provides diagnostic information and does not replace ongoing clinical management or metabolic monitoring.
Clinical Exclusion Criteria & Emergency Red Flags
- Minors under 18 years without legal guardian written informed consent as per UAE Federal Law.
- Individuals unable to provide written informed consent or those with cognitive impairment affecting decision-making capacity.
- Recent blood transfusion within the past 2 weeks or hematopoietic stem cell transplant (may interfere with DNA analysis from whole blood).
- Active systemic infection or fever at the time of sample collection – defer until clinically stable.
- Post-collection emergency: If you develop severe dizziness, bleeding, or signs of infection at the draw site, seek immediate medical care at the nearest emergency department.
This genetic test is performed in accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability governing patient consent and clinical safety, Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL), and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields governing health data security and confidentiality.
Patient FAQ & Clinical Guidance
1. What is the TAT gene and how does it relate to Tyrosinemia Type 2?
Answer: The TAT gene encodes tyrosine aminotransferase, a liver enzyme that breaks down the amino acid tyrosine. Pathogenic mutations in TAT cause toxic accumulation of tyrosine and its metabolites, leading to the characteristic triad of corneal opacities, painful palmoplantar hyperkeratosis, and potential neurological involvement if untreated. This test detects such mutations to confirm or exclude the diagnosis.
2. How is the sample collected and what is the turnaround time?
Answer: A trained phlebotomist collects a blood sample, DNA swab, or FTA card at your home using temperature-controlled cold-chain VIP mobile phlebotomy available daily from 8 AM to 11 PM. Results are securely reported within 3 to 4 weeks from sample receipt at the laboratory.
3. Is this genetic test covered by insurance in the UAE?
Answer: We verify your insurance coverage via WhatsApp before sample collection. Many UAE health insurance plans now reimburse genetic testing for inherited metabolic disorders when medically indicated and pre-authorised. Contact our billing team via WhatsApp +971 54 548 8731 (8 AM to 11 PM daily) for a coverage check.
4. What does a positive or negative result mean for my health?
Answer: A positive result confirms the presence of pathogenic variants in the TAT gene and supports a diagnosis of Tyrosinemia Type 2. A negative result significantly reduces the likelihood of this condition but does not rule out all possible genetic or acquired causes of elevated tyrosine. All results must be interpreted alongside biochemical markers and clinical symptoms by a qualified medical geneticist or metabolic specialist.
Need personal guidance? Contact our clinical team via WhatsApp +971 54 548 8731 (8 AM – 11 PM, all days).
UAE Regulatory & Data Privacy Adherence
This laboratory test strictly adheres to the UAE Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) ensuring all patient genetic data is processed lawfully, stored securely, and never shared without explicit consent. Furthermore, it complies with Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields which governs electronic health records, telemedicine, and digital health data security. The laboratory is ISO 9001:2015 accredited and operates under DHA Facility License No. 1143 at Dubai Healthcare City. All genetic information is handled with the highest level of confidentiality and is accessible only to authorised clinical personnel for the purpose of diagnosis and treatment planning.
Clinical & Logistical Metadata
| Test Name | TAT Gene Tyrosinemia Type 2 (NGS) Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3 – 4 Weeks |
| Sample Type / Matrix | Whole Blood (EDTA), Extracted DNA, or FTA Card – VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily 8 AM to 11 PM) |
| Methodology Used | Next Generation Sequencing (NGS) – Full gene coding region & flanking intronic regions |
| ICD-10-CM Code | E70.21 (Tyrosinemia), E70.20 (Disorders of tyrosine metabolism, unspecified) |
| LOINC Code | 92643-2 (Genetic testing for inherited metabolic disease panel) |
| DHA Facility License & Laboratory Address | License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | Corporate Lab Branding: DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians